US 12,012,461 B2
Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
Homer Adams, Quakertown, PA (US); Francois Gaudet, Princeton, NJ (US); Niels Van de Donk, De Boelalaan (NL); Kris Frerichs, De Boelelaan (NL); and Christie Verkleij, De Boelelaan (NL)
Assigned to Janssen Biotech, Inc., Horsham, PA (US); and Stichting VUmc, Amsterdam (NL)
Filed by Janssen Biotech, Inc., Horsham, PA (US); and Stichting VUmc, Amsterdam (NL)
Filed on May 15, 2019, as Appl. No. 16/412,831.
Claims priority of provisional application 62/842,080, filed on May 2, 2019.
Claims priority of provisional application 62/736,804, filed on Sep. 26, 2018.
Claims priority of provisional application 62/672,222, filed on May 16, 2018.
Prior Publication US 2020/0190205 A1, Jun. 18, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); C07K 16/468 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/71 (2013.01)] 18 Claims
 
1. A method of treating multiple myeloma in a subject, comprising administering a therapeutically effective amount of a BCMA×CD3 bispecific antibody to the subject to treat the multiple myeloma, wherein the subject is relapsed or refractory to treatment with a prior anti-cancer therapeutic, and wherein the BCMA×CD3 bispecific antibody consists of:
(i) one first heavy chain (HC 1), wherein the HC1 comprises an amino acid sequence having SEQ ID NO: 31, and one first light chain (LC1), wherein the LC1 comprises an amino acid sequence having SEQ ID NO: 32, and
(ii) one second heavy chain (HC2), wherein the HC2 comprises an amino acid sequence having SEQ ID NO: 41, and one second light chain (LC2), wherein the LC2 comprises an amino acid sequence having SEQ ID NO: 42.